FindTrial
Sign In

Effects of Kihito on cognitive functions in Alzheimer's disease patients

Effects of Kihito on cognitive functions in Alzheimer's disease patients - Effects of Kihito on cognitive functions in Alzheimer's disease patients

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
JPRN
Registry ID
JPRN-UMIN000023509
Enrollment
24
Registered
2016-08-22
Start date
2016-08-22
Completion date
Unknown
Last updated
2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Alzheimer&#39

Interventions

Only Cholinesterase inhibitor (aricept, for 16 weeks - Cholinesterase inhibitor plus Kihito for 16 weeks *without washout period *Tsumura Kihito (2.5 g in package
3 packages/day) Cholinesterase inhibitor plus Kihito for 16 weeks - Only Cholinesterase inhibitor (aricept, for 16 weeks *without washout period *Tsumura Kihito (2.5 g in package
3 packages/day)

Sponsors

University of Toyama
Lead Sponsor

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: Adults living in Toyama prefecture, who was diagnosed as Alzheimer's disease by cognitive testa and image analyses, and has taken any cholinesterase inhibitor more than 6 months. Score of MMSE in the person is above 15 points.

Exclusion criteria

Exclusion criteria: Persons whose MMSE score is below 14 points.

Design outcomes

Primary

MeasureTime frame
At the pre and post (for 16 weeks) administration of kKihito, these tests of cognitive functions are done; Mini Mental State Examination (MMSE)and Repeatable Battery for the Assessment (RBANS).—

Secondary

MeasureTime frame
analysis of the blood—

Countries

Japan

Contacts

Public ContactChihiro Tohda

University of Toyama Division of Neuromedical Science, Institute of Natural Medicine

chihiro@inm.u-toyama.ac.jp076-434-7646

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026